

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY COSTA RICA	2. DATE OF BIRTH			2a. AGE	3. SEX	3a. WEIGHT	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER
		Day	Month	Year				Day	Month	Year	
			PRIVACY		Unk	Female	Unk		Unk		

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)

Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)	Product	Serious	Listed	Reporter Causality	Company Causality
Blood sugar was rising [Blood glucose increased]	XIGDUO	No	No	Not Applicable	Not Related
very strong diarrhea [Diarrhoea]	XIGDUO	No	Yes	Related	Related
Medication didnt work (lack of efficacy) [Drug ineffective]	XIGDUO	No	No	Related	Not Related
Xigduo 5mg/1000mg 2 times a day (off-label) [Off label use]	XIGDUO	No	No	Not Applicable	Not Applicable

(Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) XIGDUO (DAPAGLIFLOZIN, METFORMIN) Tablet {Lot # Unknown} (Continued on Additional Information Page)		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1) 5 milligram, qd	16. ROUTE(S) OF ADMINISTRATION #1) Oral use	
17. INDICATION(S) FOR USE #1) Diabetes (Diabetes mellitus)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) Unknown	19. THERAPY DURATION #1) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)											
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) <table border="0"> <tr> <td>From/To Dates</td> <td>Type of History / Notes</td> <td>Description</td> </tr> <tr> <td>Unknown to Ongoing</td> <td>Indication</td> <td>Diabetes (Diabetes)</td> </tr> <tr> <td>Unknown</td> <td>Historical Condition</td> <td>Diarrhea (Diarrhoea)</td> </tr> </table>			From/To Dates	Type of History / Notes	Description	Unknown to Ongoing	Indication	Diabetes (Diabetes)	Unknown	Historical Condition	Diarrhea (Diarrhoea)
From/To Dates	Type of History / Notes	Description									
Unknown to Ongoing	Indication	Diabetes (Diabetes)									
Unknown	Historical Condition	Diarrhea (Diarrhoea)									

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER AstraZeneca Serban Ghiorgiu 1 Medimmune Way Gaithersburg, Maryland 20878 UNITED STATES Phone: +1 301-398-0000		26. REMARKS World Wide #: CR-ASTRAZENECA-202508CAM001438CR Study ID: PSP-23269 Case References: CR-AstraZeneca-CH-00924257A
	24b. MFR CONTROL NO. 202508CAM001438CR	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 04-AUG-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	NAME AND ADDRESS WITHHELD.
DATE OF THIS REPORT 08-AUG-2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:	

08-Aug-2025 15:00

ADDITIONAL INFORMATION

7+13. DESCRIBE REACTION(S) continued

Case Description: A solicited report has been received from a consumer in Patient Support Program. The report concerns a female patient born in 1932.

The patient's past and current medical history included diarrhea (dates not reported).

No concomitant products were reported.

The patient started treatment with Xigduo (dapagliflozin, metformin) (batch number(s) Unknown) 5 milligram qd, Oral use, on an unknown date for diabetes.

On an unknown date, the patient experienced medication didnt work (lack of efficacy) (preferred term: Drug ineffective), blood sugar was rising (preferred term: Blood glucose increased), severe very strong diarrhea (preferred term: Diarrhoea) and xigduo 5mg/1000mg 2 times a day (off-label) (preferred term: Off label use).

The report described off-label use for Xigduo. The reported term was xigduo 5mg/1000mg 2 times a day (off-label) (preferred term: Off label use). The report described lack of effect for Xigduo. The reported term was "medication didnt work (lack of efficacy)" (preferred term: Drug ineffective).

Treatment with Xigduo (dapagliflozin, metformin) was discontinued during 2025.

The outcome of the event(s) of medication didnt work (lack of efficacy) and xigduo 5mg/1000mg 2 times a day (off-label) was unknown. At the time of reporting, the event blood sugar was rising and very strong diarrhea was ongoing.

The events were considered non-serious.

The reporter did not assess causality for blood sugar was rising and xigduo 5mg/1000mg 2 times a day (off-label).The reporter considered that there was a reasonable possibility of a causal relationship between Xigduo and the following event(s): medication didnt work (lack of efficacy) and very strong diarrhea.

The company physician did not consider that there was a reasonable possibility of a causal relationship between Xigduo and the following event(s): blood sugar was rising and medication didnt work (lack of efficacy). The company physician considered that there was a reasonable possibility of a causal relationship between Xigduo and the following event(s): very strong diarrhea.

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) XIGDUO (DAPAGLIFLOZIN, METFORMIN) Tablet; Regimen #2	5 milligram, bid; Oral use	Diabetes (Diabetes mellitus)	Unknown / 2025; Unknown